Literature DB >> 23245832

Medulloblastoma.

F Bartlett1, R Kortmann, F Saran.   

Abstract

Medulloblastomas are primary malignant embryonal tumours of the central nervous system. They are the most common childhood central nervous system tumour, but are rare in the adult population. They arise infratentorially in the cerebellum or fourth ventricle and hence the most common presenting symptoms are those associated with raised intracranial pressure. Several histological subtypes have been described, although the classical and desmoplastic subtypes account for the majority. Recent advances in molecular biology and cytogenetics have led to an improved understanding of the genetic abnormalities and alterations in cell signalling pathways associated with medulloblastomas, including how these relate to patient outcome. The Modified Chang Staging System is still in use, but a number of other factors, including age, completeness of resection, histological subtype and genetic markers now contribute to treatment decisions and prognostication. Patients are currently classified as being either standard or high risk in order to stratify treatment. There has been an improvement in survival of all groups over the past 20 years. A multimodality approach is the cornerstone of treatment and recent trials have concentrated on ascertaining the most efficacious treatment combinations and timings for each patient group. Advances in surgical techniques have allowed a greater attainment of the two primary surgical goals: restoring normal cerebrospinal fluid (CSF) flow and maximal tumour resection. Radiotherapy to the craniospinal axis with a boost to the posterior fossa has been standard practice, but improvement in radiotherapy techniques and quality control has enabled optimisation of the trade-off between tumour control and normal tissue late toxicities. Combination chemotherapy is usually given adjuvantly, although it may be used to delay or avoid the use of radiotherapy in infants. In the future, the treatment of medulloblastoma will probably become increasingly individualised, based on patient-specific genetic features. Attention will be focussed not only on improving survival, but also on maintaining quality of life.
Copyright © 2012 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23245832     DOI: 10.1016/j.clon.2012.09.008

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  24 in total

Review 1.  Targeted treatment for sonic hedgehog-dependent medulloblastoma.

Authors:  Mark W Kieran
Journal:  Neuro Oncol       Date:  2014-06-20       Impact factor: 12.300

2.  Fast imaging employing steady-state acquisition (FIESTA) MRI to investigate cerebrospinal fluid (CSF) within dural reflections of posterior fossa cranial nerves.

Authors:  David J Noble; Daniel Scoffings; Thankamma Ajithkumar; Michael V Williams; Sarah J Jefferies
Journal:  Br J Radiol       Date:  2016-09-29       Impact factor: 3.039

3.  Does size matter? Minimally invasive approach in pediatric neurosurgery--a review of 125 minimally invasive surgeries in children: clinical history and operative results.

Authors:  M Renovanz; A K Hickmann; A Gutenberg; M Bittl; N J Hopf
Journal:  Childs Nerv Syst       Date:  2015-02-17       Impact factor: 1.475

Review 4.  Sox2: regulation of expression and contribution to brain tumors.

Authors:  Sheila Mansouri; Romina Nejad; Merve Karabork; Can Ekinci; Ihsan Solaroglu; Kenneth D Aldape; Gelareh Zadeh
Journal:  CNS Oncol       Date:  2016-05-27

5.  Chemotherapy increases long-term survival in patients with adult medulloblastoma--a literature-based meta-analysis.

Authors:  Selin Kocakaya; Christoph Patrick Beier; Dagmar Beier
Journal:  Neuro Oncol       Date:  2015-09-10       Impact factor: 12.300

6.  Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord.

Authors:  Yuxuan Wang; Simeon Springer; Ming Zhang; K Wyatt McMahon; Isaac Kinde; Lisa Dobbyn; Janine Ptak; Henry Brem; Kaisorn Chaichana; Gary L Gallia; Ziya L Gokaslan; Mari L Groves; George I Jallo; Michael Lim; Alessandro Olivi; Alfredo Quinones-Hinojosa; Daniele Rigamonti; Greg J Riggins; Daniel M Sciubba; Jon D Weingart; Jean-Paul Wolinsky; Xiaobu Ye; Sueli Mieko Oba-Shinjo; Suely K N Marie; Matthias Holdhoff; Nishant Agrawal; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Chetan Bettegowda
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-20       Impact factor: 11.205

7.  Is there an increased risk of spinal relapse in standard-risk medulloblastoma/primitive neuroectodermal tumor patients who receive only a reduced dose of craniospinal radiotherapy?

Authors:  Akıncı Burcu; Çetingül Nazan; Özdemir Özgür; Kamer Serra; Kantar Mehmet; Aksoylar Serap; Demirağ Bengü; Vergin Canan; Öniz Haldun; Kansoy Savaş; Turhan Tuncer; Akalın Taner; Ertan Yeşim; Kitiş Ömer; Anacak Yavuz
Journal:  Childs Nerv Syst       Date:  2018-06-04       Impact factor: 1.475

8.  Response to "Reply to 'Survival analysis for apparent diffusion coefficient measures in children with embryonal brain tumors,' by Grech-Sollars et al".

Authors:  Matthew Grech-Sollars; Dawn E Saunders; Kim P Phipps; Jonathan D Clayden; Chris A Clark
Journal:  Neuro Oncol       Date:  2013-03       Impact factor: 12.300

Review 9.  Core deficits and quality of survival after childhood medulloblastoma: a review.

Authors:  Mathilde Chevignard; Hugo Câmara-Costa; François Doz; Georges Dellatolas
Journal:  Neurooncol Pract       Date:  2016-08-26

10.  Quality of survival and cognitive performance in children treated for medulloblastoma in the PNET 4 randomized controlled trial.

Authors:  Hugo Câmara-Costa; Kim S Bull; Colin Kennedy; Andreas Wiener; Gabriele Calaminus; Anika Resch; Virginie Kieffer; Clémence Lalande; Geraldina Poggi; Katja von Hoff; Jacques Grill; François Doz; Stefan Rutkowski; Maura Massimino; Rolf-Dieter Kortmann; Birgitta Lannering; Georges Dellatolas; Mathilde Chevignard
Journal:  Neurooncol Pract       Date:  2017-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.